Direct and Indirect Regulators of Epithelial-Mesenchymal Transition (EMT)-mediated Immunosuppression in Breast Carcinomas.

The epithelial-to-mesenchymal transition (EMT), which conveys epithelial (E) carcinoma cells to quasi-mesenchymal (qM) states, enables them to metastasize and acquire resistance to certain treatments. Murine tumors composed of qM mammary carcinoma cells assemble an immunosuppressive tumor microenvironment (TME) and develop resistance to anti-CTLA4 immune checkpoint blockade therapy (ICB), unlike their E counterparts. Importantly, minority populations of qM cells within a tumor can cross-protect their more E neighbors from immune attack. The underlying mechanisms of immunosuppression and cross-protection have been unclear. We demonstrate that abrogation of qM carcinoma cell-derived factors (CD73, CSF1 or SPP1) prevents the assembly of an immunosuppressive TME and sensitizes otherwise refractory qM tumors partially or completely to anti-CTLA4 ICB. Most strikingly, mixed tumors in which minority populations of carcinoma cells no longer express CD73, are now sensitized to anti-CTLA4 ICB. Finally, loss of CD73 also enhances the efficacy of anti-CTLA4 ICB during the process of metastatic colonization.

[1]  D. Pe’er,et al.  Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma , 2019, Nature Medicine.

[2]  A. Ribas,et al.  Tumour-intrinsic resistance to immune checkpoint blockade , 2019, Nature Reviews Immunology.

[3]  Cheryl F. Lichti,et al.  MHC-II neoantigens shape tumor immunity and response to immunotherapy , 2019, Nature.

[4]  X. Zhang,et al.  Immuno-subtyping of breast cancer reveals distinct myeloid cell profiles and immunotherapy resistance mechanisms , 2019, Nature Cell Biology.

[5]  G. Coukos,et al.  Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function , 2019, Front. Immunol..

[6]  R. Weinberg,et al.  Acquisition of a hybrid E/M state is essential for tumorigenicity of basal breast cancer cells , 2019, Proceedings of the National Academy of Sciences.

[7]  E. V. Van Allen,et al.  Genomic correlates of response to immune checkpoint blockade , 2019, Nature Medicine.

[8]  F. Hodi,et al.  Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade , 2019, Nature Immunology.

[9]  Brian Ruffell,et al.  Macrophages as regulators of tumour immunity and immunotherapy , 2019, Nature Reviews Immunology.

[10]  H. Nishikawa,et al.  Regulatory T cells in cancer immunosuppression — implications for anticancer therapy , 2019, Nature Reviews Clinical Oncology.

[11]  Daniel E. Speiser,et al.  Intratumoral Tcf1+PD‐1+CD8+ T Cells with Stem‐like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy , 2019, Immunity.

[12]  R. Weinberg,et al.  New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer , 2018, Nature reviews. Molecular cell biology.

[13]  A. Ohta,et al.  A2A Adenosine Receptor Gene Deletion or Synthetic A2A Antagonist Liberate Tumor-Reactive CD8+ T Cells from Tumor-Induced Immunosuppression , 2018, The Journal of Immunology.

[14]  R. Weinberg,et al.  Epithelial-Mesenchymal Transition Induces Podocalyxin to Promote Extravasation via Ezrin Signaling , 2018, Cell reports.

[15]  E. Furth,et al.  EMT Subtype Influences Epithelial Plasticity and Mode of Cell Migration. , 2018, Developmental cell.

[16]  Paolo A Ascierto,et al.  Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. , 2018, Cancer cell.

[17]  Nir Hacohen,et al.  Resistance to checkpoint blockade therapy through inactivation of antigen presentation , 2017, Nature Communications.

[18]  Dana Pe’er,et al.  Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade , 2017, Cell.

[19]  R. Weinberg,et al.  Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells , 2017, The Journal of experimental medicine.

[20]  H. Geng,et al.  Reversing the polarization of tumor‐associated macrophages inhibits tumor metastasis , 2017, International immunopharmacology.

[21]  J. Thiery,et al.  New insights into the role of EMT in tumor immune escape , 2017, Molecular oncology.

[22]  R. Weinberg,et al.  Epithelial-to-Mesenchymal Transition Contributes to Immunosuppression in Breast Carcinomas. , 2017, Cancer research.

[23]  R. Weinberg,et al.  Emerging Biological Principles of Metastasis , 2017, Cell.

[24]  J. Kutok,et al.  Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells , 2016, Nature.

[25]  J. Wargo,et al.  Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy , 2016, Cell.

[26]  R. Weinberg,et al.  Inflammation Triggers Zeb1-Dependent Escape from Tumor Latency. , 2016, Cancer research.

[27]  Amir Mehdi. Ansari,et al.  Cellular GFP Toxicity and Immunogenicity: Potential Confounders in in Vivo Cell Tracking Experiments , 2016, Stem Cell Reviews and Reports.

[28]  T. Graeber,et al.  Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. , 2016, The New England journal of medicine.

[29]  M. Shipp,et al.  NLRC5/MHC class I transactivator is a target for immune evasion in cancer , 2016, Proceedings of the National Academy of Sciences.

[30]  P. Steeg,et al.  Targeting metastasis , 2016, Nature Reviews Cancer.

[31]  J. Sosman,et al.  Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma , 2016, Cell.

[32]  Jedd D. Wolchok,et al.  PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations , 2016, Science Translational Medicine.

[33]  David K. Finlay,et al.  TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway , 2016, Science Signaling.

[34]  Jing Wang,et al.  Epithelial–Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma , 2016, Clinical Cancer Research.

[35]  A. Ribas.  Adaptive Immune Resistance: How Cancer Protects from Immune Attack. , 2015, Cancer discovery.

[36]  R. Weinberg,et al.  Distinct EMT programs control normal mammary stem cells and tumour-initiating cells , 2015, Nature.

[37]  T. Gajewski,et al.  Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity , 2015, Nature.

[38]  S. Goerdt,et al.  Macrophage activation and polarization: nomenclature and experimental guidelines. , 2014, Immunity.

[39]  Martin Turcotte,et al.  Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer , 2014, Expert opinion on therapeutic targets.

[40]  Samy Lamouille,et al.  Molecular mechanisms of epithelial–mesenchymal transition , 2014, Nature Reviews Molecular Cell Biology.

[41]  R. Gomis,et al.  Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. , 2012, The Journal of clinical investigation.

[42]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[43]  Wenjun Guo,et al.  Slug and Sox9 Cooperatively Determine the Mammary Stem Cell State , 2012, Cell.

[44]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[45]  Sophia Hsin-Jung Li,et al.  Paracrine and Autocrine Signals Induce and Maintain Mesenchymal and Stem Cell States in the Breast , 2011, Cell.

[46]  A. Mantovani,et al.  Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm , 2010, Nature Immunology.

[47]  J. Settleman,et al.  EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer , 2010, Oncogene.

[48]  Bin Zhang.  CD73: a novel target for cancer immunotherapy. , 2010, Cancer research.

[49]  Jeffrey W. Pollard,et al.  Macrophage Diversity Enhances Tumor Progression and Metastasis , 2010, Cell.

[50]  M. Smyth,et al.  Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis , 2010, Proceedings of the National Academy of Sciences.

[51]  M. Nieto.  Epithelial-Mesenchymal Transitions in development and disease: old views and new perspectives. , 2009, The International journal of developmental biology.

[52]  Yutaka Kawakami,et al.  Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. , 2009, Cancer cell.

[53]  Pornpimol Charoentong,et al.  ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks , 2009, Bioinform..

[54]  A. Puisieux,et al.  Generation of Breast Cancer Stem Cells through Epithelial-Mesenchymal Transition , 2008, PloS one.

[55]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[56]  A. Sica,et al.  Plasticity of Macrophage Function during Tumor Progression: Regulation by Distinct Molecular Mechanisms1 , 2008, The Journal of Immunology.

[57]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[58]  Silvano Sozzani,et al.  The chemokine system in diverse forms of macrophage activation and polarization. , 2004, Trends in immunology.

[59]  Brad T. Sherman,et al.  DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.

[60]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[61]  D. Skelton,et al.  The enhanced green fluorescent protein (eGFP) is minimally immunogenic in C57BL/6 mice , 2001, Gene Therapy.

[62]  F. Marincola,et al.  Status of Immune Oncology: Challenges and Opportunities. , 2020, Methods in molecular biology.

[63]  W. Hahn,et al.  Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. , 2001, Genes & development.